Navigation Links
Thomson Reuters Adds Routes of Synthesis Data to Its Newport Horizon Premium and Newport Vision Premium Solutions
Date:6/4/2008

LONDON and PHILADELPHIA, June 5 /PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today announced the addition of Prous Science routes of synthesis (ROS) data to the Newport Horizon Premium and Newport Vision Premium solutions. An ROS focused search allows users to identify active pharmaceutical ingredients (APIs) according to an intermediate or reagent used, number of available routes or by patents referenced in a given route. Provided free of charge to current subscribers of the Premium systems, this new dataset, which provides an exciting compliment to the kilogram demand data released in March, enhances product targeting, business development and competitive intelligence by helping users to understand better the chemistry and manufacture of APIs.

The true or original manufacturing process used for a particular API is usually well protected by patents, making it challenging to devise equivalent, cheaper or more efficient processes without infringing on the originator's intellectual property. The new dataset will help to remedy this by providing extensive information for more than 2,500 APIs, consisting of:

-- Full chemical name

-- CAS number

-- Synthesis route diagram

-- Text commentary (with each step indexed to the diagram)

-- Patent references (linked to the patent page)

-- Intermediate chemicals and CAS numbers

-- Reagent chemicals and CAS numbers

-- Scientific journal references

"Understanding the 'recipe' of how a particular active ingredient is made -- or could be made -- is of vital importance to API manufacturers, generic companies and innovators," said Mike Chace-Ortiz, Senior Director, Product Strategy, Thomson Reuters. "By providing access to this important data, Newport Horizon Premium and Newport Vision Premium now allow our customers to gauge which patents are involved, what raw materials are needed, the cost and complexity of the process and whether specialized equipment or facilities must be bought or constructed."

For further information on Thomson Reuters API Intelligence solutions, visit: http://scientific.thomsonreuters.com/newport/

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to http://www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline
2. Thomson Reuters Honors Temple University Health System for Initiative That Cut Costs $64 Million and Grew Clinical Service Lines
3. New Thomson Reuters Biomarkers Report Shines a Light on Revolutionary New Area of Drug Development
4. Thomson Healthcare Undertakes Medical Staff Development Project for IASIS Healthcare
5. Thomson Scientific To Honor Australias Top Researchers With Dedicated Australian Research Day
6. Thomson Healthcare Announces Enhancements to Order Sets Solution
7. Thomson Healthcares Clinical Xpert Navigator Tops KLAS Annual Performance Ranking in Mobile Data Systems for Sixth Consecutive Year
8. Thomson Scientific Introduces a New Quarterly Report Identifying the Movers and Shakers in the U.S. Generics Industry
9. Jobson Medical Information LLC Acquires CenterWatch and New England IRB From Thomson Healthcare
10. Saint Barnabas Health Care System Expands Business Relationship with Thomson Healthcare
11. Protalix BioTherapeutics prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... A new ... Orthopaedic Surgeons , points out that therapeutic modalities (physical therapy) is an important ... to the report, a wider scope of physical therapy options is showing promising ...
(Date:8/22/2017)... ... August 22, 2017 , ... The old adage ... as simple as eating healthy foods. But this well-known piece of nutrition advice ... or breaking apart carbohydrates—depends not only on properties of the food but also ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... solutions, announced recently the availability of a new professional fee E/M leveling calculator ... their service to the healthcare industry. E/M coding is complex which supports the ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Wilderness Voices”: a collection ... travel. “Wilderness Voices” is the creation of published author, Martha McKown, an ordained ... was inspired as a very young child when her older sisters studied High School ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... the Founder and Managing Member for t4 Leadership Development & Consulting. He has ... his definition of “success”: physician leadership development, servant leadership, data driven process improvement, ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Mostyn Law and Gulf Coast Regional Blood Center to host ... Mostyn Law family has had 3 members that needed ... Mostyn Law is partnering with Gulf Coast Regional Blood Center ... Blood supplies are running low. Gulf Coast Regional Blood Center,s ... August. That is why the blood center reached out to ...
(Date:8/15/2017)... Calif. , Aug. 15, 2017  AOTI Inc. announced today ... Oxygen Therapy Inc., has recently opened a New York City Office ... ever-increasing usage of its unique Topical Wound Oxygen (TWO 2 ) ... by the Accreditation Commission for Health Care (ACHC) under the company,s ... ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
Breaking Medicine Technology: